sisteinin
Sisteinin is a synthetic cannabinoid receptor agonist, a class of psychoactive substances that interact with the body's endocannabinoid system. It was first synthesized in 2014 and has since gained attention due to its potent effects and relatively low detection rates in drug tests. Sisteinin is structurally similar to other synthetic cannabinoids, such as JWH-018 and JWH-073, and is believed to act as an agonist at the CB1 and CB2 receptors, which are part of the endocannabinoid system.
The primary effects of sisteinin are similar to those of other synthetic cannabinoids, including euphoria, increased
Due to its potent effects and the lack of regulation in some regions, sisteinin has been associated
Research on sisteinin is limited, and more studies are needed to fully understand its effects, potential risks,